Company Overview - Parse Biosciences, co-founded in 2018 by Alex Rosenberg and Charles Roco, specializes in single-cell RNA sequencing and has grown to 110 employees [3] - The company initially launched as Split Biosciences before rebranding to Parse Biosciences [3] - Parse has raised over $50 million from investors, including a $41.5 million Series B round in 2022 [4] Acquisition Details - Parse Biosciences is set to be acquired by Qiagen in a cash deal valued at $225 million, with the transaction expected to close in December [2][6] - The acquisition is subject to regulatory clearance under the U.S. Hart-Scott-Rodino Antitrust Improvements Act [6] Financial Impact - The acquisition is projected to add approximately $40 million in sales to Qiagen's fiscal year 2026 [4] Market Position - Parse currently serves around 3,000 customers across more than 40 countries [4] - Qiagen, the acquiring company, has a global customer base of 500,000 and employs about 5,700 people across 35 locations [6] Technology and Applications - RNA profiling by Parse helps scientists understand active genes, which is crucial for distinguishing different cell types [5]